Skip to main content

Table 6 Multivariate analysis of variables associated with increased referral rate of patients receiving cardiotoxic chemotherapy from oncology clinic to cardio-oncology or cardiology clinic

From: Healthcare disparities in cardio oncology: patients receive same level of surveillance regardless of race at a safety net hospital

  Odds Ratio Confidence Interval P-value
Race
 Black Reference   
 White 1.47 0.50–4.32 p = 0.48
 Hispanic 1.34 0.43–4.19 p = 0.62
 Other 0.42 0.05–3.74 p = 0.43
Age 0.96 0.93–1.00 p = 0.08
Gender
 Male Reference   
 Female 0.20 0.03–1.33 p = 0.10
Insurance
 Private Reference   
 Medicare 0.48 0.13–1.84 p = 0.29
 Medicaid 0.69 0.08–5.77 p = 0.74
 Self 0.23 0.03–1.57 p = 0.13
Income by ZIP code*
 Quartile 1 Reference   
 Quartile 2 3.61 0.95–13.67 p = 0.06
 Quartile 3 5.35 1.35–21.26 p = 0.017
 Quartile 4 4.38 1.00–19.13 p = 0.049
Risk factors
 HTN 6.85 2.68–17.52 p = 0.0001
 HLD 1.07 0.41–2.81 p = 0.90
 CAD 0.15 0.01–1.63 p = 0.12
 Arrhythmia 1.82 0.35–9.52 p = 0.48
 DM 1.78 0.67–4.75 p = 0.25
 Smoking 1.18 0.47–2.99 p = 0.73
 FH 0.79 0.29–2.13 p = 0.64
 Age > 65 4.01 0.10–16.17 p = 0.051
Cancer type
 Breast cancer Reference   
 Other cancer^ 0.12 0.02–0.74 p = 0.02
Cancer stage
 Stage 1 Reference   
 Stage 2 0.31 0.05–1.83 p = 0.20
 Stage 3 0.16 0.02–1.33 p = 0.09
 Stage 4 0.23 0.03–1.78 p = 0.16
Chemotherapy
 Doxorubicin 1.49 0.34–6.53 p = 0.60
 Herceptin 0.70 0.12–3.97 p = 0.68
Medications pre-chemotherapy
 BB 2.04 0.46–9.06 p = 0.35
 ACEI/ARB 0.16 0.04–0.70 p = 0.01
 Diuretic 2.31 0.24–22.47 p = 0.47
 CCB 1.28 0.28–5.91 p = 0.75
 ASA 2.28 0.42–12.49 p = 0.34
 Statin 0.66 0.12–3.63 p = 0.63
\